Principles of Bone Biology is the essential resource for anyone involved in the study of bones. It is the most comprehensive, complete, up-to-date source of information on all aspects of bones and bone biology in one convenient source. Written and published in less than one year, it will become an indispensable resource for any scientific or medical library. This, second edition, details countless advances over the past five years, both by updating old chapters and providing additional material. It takes the reader from the basic elements of fundamental research to the most sophisticated concepts in therapeutics.
The most current and timely source of information about the biology and pathology of bone Provides succinct coverage of the subject Contributors include over 200 of the most respected researchers in the field Extensive table of contents and index for easy reference Easy-to-read and highly informative to both the newcomer and the initiated to the field Spans the spectrum from molecular biology to in vivo pharmacology Complete bibliography with each entry fully referenced for additional background reading First edition was selected by Doody Publishing as one of the 250 Best Health Science books published in 1996
Researchers, professionals, and academic clinicians in bone, endocrinology, and related disciplines.
Molecular Basis of PTH Overexpression Familial Benign Hypocalciuric Hypercalcemia and Neonatal Primary Hyperparathyroidism Multiple Endocrine Neoplasia Type I The Role of the RET Proto-oncogene in Multiple Endocrine Neoplasia Type 2 Systemic Factors in Skeletal Manifestations of Malignancy Local Factors in Skeletal Malignancy Molecular Basis of PTH Underexpression Jansen's Metaphyseal Chondrodysplasia & Blomstrand's Lethal Chondrodysplasia: Two Genetic Disorders Caused by PTH/PTHrP Receptor Mutations Signal Transduction via G Proteins; Pseudohypoparathyroidism Other Skeletal Diseases Resulting from G Protein Defects - Fibrous Dysplasia & McCune-Albright Syndrome Osteogenesis Imperfecta Hereditary Deficiencies in Vitamin D Action Oncogenic Osteomalacia Osteopetrosis Hypophosphatasia: Nature's Window on Alkaline Phosphatase Function in Man Paget's Disease of Bone Genetic Determinants of Bone Mass Pathophysiology of Osteoporosis Evaluation of Risk for Osteoporosis FracturesPART III: PHARMACOLOGIC MECHANISMS OF THERAPEUTICS
Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone Calcium Calcium Receptors as Novel Drug Targets Bisphosphonates: Mechanisms of Action Fluoride in Osteoporosis The Pharmacology of Estrogens in Osteoporosis Pharmacologic Mechanisms of Therapeutics: Vitamin D & Analogs Molecular and Clinical Pharmacology of Calcitonin Growth Hormone and Insulin-like Growth Factor-I Treatment for Metabolic Bone Diseases Anabolic Steroid Effects on Bone in Women Estrogen Effects on Bone in the Male Skeleton Mechanisms of Exercise Effects on BonePART IV: METHODS IN BONE RESEARCH
Application of Transgenic Mice to Problems of Skeletal Bone Use of Cultured Osteoblastic Cells to Identify and Characterize Transcriptional Regulatory Complexes Current Methodologic Issues in Cell & Tissue Culture Biochemical Markers of Bone Metabolism Methods and Clinical Issues in Bone Densitometry and Quantitative Ultrasonometry Controversies in Bone Mass Measurement Macro and Micro Imaging of Bone Architecture Transilial Bone Biopsy Animal Models in Osteoporosis Research Defining the Genetics of Osteoporosis - Using the Mouse to Understand Man
- No. of pages:
- © Academic Press 2002
- 9th January 2002
- Academic Press
- eBook ISBN:
John P. Bilezikian, MD, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach. Dr. Bilezikian belongs to a number of professional societies including the American Society for Bone and Mineral Research, of which he served as President, 1995-1996 and the International Society of Clinical Densitometry, of which he served as President, 1999-2001. He serves on the Board of Governors of the International Osteoporosis Foundation (1998-present) and on its Committee of Scientific Advisors (2001-present). He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004) and as Senior Associate Editor of the Journal of Bone and Mineral Research (2008-2012). He is Executive Advisory Editor of Bone Research (2013-present). His books include Editor-in-Chief of The Parathyroids [1994, 2001, 2014], and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008) and Osteoporosis in Men (2010). He served as co-chair of the last three NIH Workshops on Primary Hyperparathyroidism (2002, 2008, 2013). He is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the American Society for Bone and Mineral Research (ASBMR) for Excellence in Clinical Research and the First Annual Global Leadership Award of the International Society of Clinical Densitometry. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of The Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. His publications number over 700.
Columbia University, New York, New York, U.S.A.
Dr. Raisz is Professor of Medicine and Program Director of the General Clinical Research Center at the University of Connecticut Health Center. He has been carrying out laboratory and clinical studies in the field of osteoporosis and bone metabolism for over 40 years. He has mentored a large number of investigators in these areas both here at the University of Connecticut and previously at the University of Rochester School of Medicine. His current studies include an analysis of the effects of estrogen and androgen on the expression of cytokines and growth factors in bone, which is being carried out in both humans and animal models, studies of the role of prostaglandins in bone metabolism using transgenic mice, studies on the effects of progestins on bone turnover in postmenopausal women and tissue culture and animal studies on new antiresorptive and anabolic agents carried out in collaboration with the pharmaceutical industry.
University of Connecticut, Farmington, U.S.A.
Dr. Rodan graduated from the Hebrew University Medical School (Jerusalem) in 1965, had two years residency in oncology and obtained a Ph.D. in chemistry in 1970 from the Weizmann Institute of Science, Israel. In 1970, he joined the University of Connecticut, where he became chairman of the Department of Oral Biology in 1978. In 1985, he was recruited by Merck to head the Department of Bone Biology and Osteoporosis Research and, since 1986, holds a joint appointment at the University of Pennsylvania as Adjunct Professor of Pathology.
The scientific contributions of Dr. Rodan and his colleagues include: establishment and characterization of osteoblastic cell lines in culture, which helped define the osteoblastic phenotype, the sequential expression of phenotypic genes, the interaction between osteoblasts and osteoclasts, and the development of a sensitive parathyroid hormone bioassay, which eventually led to the purification of parathyroid hormone-related peptide; other contributions include bone cell responses to mechanical stimuli and the role of prostaglandin E in that process. At Merck, Dr. Rodan initiated the effort which led to the development of the osteoporosis drug Fosamax and contributed to the understanding of the mode of action of bisphosphonates.
Dr. Rodan has served on NIH study sections, council and other advisory panels; he has been an Associate Editor of the Journal of Bone and Mineral Research, is currently Associate Editor of Bone, and member of several editorial boards. Dr. Rodan has been council member, program chairman and president of ASBMR; member of the Board of Directors of the National Osteoporosis Foundation and is currently president elect of the International Bone and Mineral Society. Dr. Rodan is the recipient of the Kennedy prize from the Weizmann Institute of science, the Neuman prize from the ASBMR, the Pioneer Award of the National Osteoporosis Foundation and the Goldhaber award of Harvard School of Dental Medicine.
Merck Research Labs, West Point, Pennsylvania, U.S.A.
"It is a monumental text…The authors are experts in the field from several countries. The second edition contains ten new chapters. Each chapter is well illustrated and referenced. Of interest to all endocrinologists and bone biologists, including gynecologists and nephrologists." - Zvi Laron, THE JOURNAL OF ENDOCRINE GENETICS, 2004 "It is a monumental text, containing 96 chapters...The authors are experts in the field from several countries. ...Of interest to all endocrinologists and bone biologists, including gynecologists and nephrologists" —JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2002) "...a comprehensive resource for scientists and clinicians involved in the fields of bone biology, metabolic bone disease and osteoporosis." —Vivian P. Bykerk University of Toronto, Mount Sinai Hospital for THE JOURNAL OF RHEUMATOLOGY (2002)